Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
The Risk of Parkinson's Disease with Exposure to Pesticides, Farming, Well Water, and Rural Living
Neurol 50:1346-1350, Gorell,J.M.,et al, 1998
Occupational Exposures to Metals as Risk Factors for Parkinson's Disease
Neurol 48:650-658, Gorell,J.M.,et al, 1997
Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996
Neurological Sequelae of Cyanide Intoxication-The Patterns of Clinical MRI & Pet Findings
Ann Neurol 38:825-828, Rosenow,F.,et al, 1995
Levodopa Failure in Chronic Manganism
Neurol 44:1600-1602, 15831994., Lu,C-S.,et al, 1994
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Parkinsonism Caused by Petroleum Waste Ingestion
Neurol 44:1051-1054, Tetrud,J.W.,et al, 1994
Unsuspected, Surreptitious Drug-Induced Parkinsonism
Neurol 42:459, Albanese,A.,et al, 1992
Acute and Persistent Parkinsonism after Use of Diquat
Neurol 42:261-263, Sechi,G.P.,et al, 1992
Delayed Encephalopathy after Acute Carbon Monoxide Intoxication:MR Imaging Features & Cerebral White Matter Lesions
Radiology 184:117-122, Chang,K.H.,et al, 1992
Parkinson's Disease and Exposure to Agricultural Work and Pesticide Chemicals
Neurol 42:1328-1335, Semchuk,K.M.,et al, 1992
Lesions of Basal Ganglia Due to Disulfiram Neurotoxicity
JNNP 55:925-929, Laplane,D.,et al, 1992
Environmental Risk Factors in Siblings with Parkinson's Disease
Arch Neurol 48:287-289, Wong,G.F.,et al, 1991
Environmental Risk Factors in Parkinson's Disease
Neurol 40:1218-1221, Koller,W.,et al, 1990
Environmental Factors and Parkinson's Disease:A Case-Control Study in China
Neurol 39:660-664, Tanner,C.M.,et al, 1989
Chronic Manganese Intoxication
Arch Neurol 46:1104-1106, Huang,C.C.,et al, 1989
Extrapyramidal and Other Neurologic Manifestations Associated with Carbon Disulfide Fumigant Exposure
Arch Neurol 45:537-540, Peters,H.A.,et al, 1988
Neurological Clues from Environmental Neurotoxins
BMJ 295:346-347, Martyn,C.N., 1987
Locus Ceruleus Lesions & Eosinophilic Inclusions in MPTP-Treated Monkeys
Ann Neurol 20:449-455, Forno,L.S.,et al, 1986
Alzheimer's Disease, Parkinson's Disease, & Motoneurone Disease:Abiotropic Interaction Between Ageing & Environment
Lancet 2:1067-1068, Calne,D.B.,et al, 1986
Paraquat & Parkinson's Disease
Neurol 36:1147, Koller,W.C., 1986
Aetiology of Parkinson's Disease
Lancet 2:1457-1459, Calne,D.B.,et al, 1983
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Parkinsons Disease Beyond 20 Years
JNNP 86:849-855, Cilia, R.,et al, 2015
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Restless Genital Syndrome in Parkinson Disease
JAMA Neurol 71:1559-1561, Aquino, C.C.,et al, 2014
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Practice Parameter: Treatment of Nonmotor Symptoms of Parkinson Disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:924-931, Zesiewicz,T.A.,et al, 2010
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
A Double-blind Placebo-controlled Trial of Botulinum Toxin B for Sialorrhea in Parkinson's Disease
Neurol 62:37-40, Ondo,W.G.,et al, 2004